Company Overview and News

Global appetite for NZ yield stocks on pause, Harbour Asset's Bascand says

Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.

NZ shares fall despite global recovery

New Zealand shares fell less than some analysts feared as the local market returned from a day off and global volatility settled down from selling earlier in the week. The dual-listed Australian banks and growth stocks declined.

NZ shares fall after month-end positioning

New Zealand shares fell on the first day of the month in a muted trading session after institutional investors staked out positions yesterday. Contact Energy and Summerset Group Holdings declined.

Brokers Picks: The 2017 results look good

It has been a good year for local equities. In fact we're not far from being able to call it a good decade with the NZX bull-run moving into its ninth year in 2018.

Stock Takes: Cash injection needed for Orion Health?

Questions are being raised about whether Orion Health will need to raise more cash after its poor half-year result.

NZ shares gain with Fletcher 'bargain-hunting'; Sky TV falls, Orion Health hits record low

New Zealand shares gained, with Fletcher Building rising as investors were lured back after its recent weakness, while Orion Health Group hit a record low.

Brian Gaynor: Cancer firm has the technology, but where's the profit?

Pacific Edge's share price tumbled 27.7 per cent this week, from 47c to 34c, after it announced a fully underwritten 1-for-6 rights issue at 32c a share that will raise $21.3 million.

NZ shares rise as growth stocks A2, Xero, extend gains

New Zealand shares rose as the export-orientated growth stocks A2 Milk and Xero extended recent gains, while insurer CBL Corp declined.

Cellmid Limited gets a boost for its midkine assets

Cellmid Limited (ASX:CDY) has had results from a melanoma study related to midkine published by the prestigious and renowned journal, Nature.

NZ shares edge up as budget, earnings dominate

New Zealand shares edged higher on relatively small volumes as investors were preoccupied with the government's budget and a slew of earnings, including Metro Performance Glass, which reported a boost in sales on its Australian expansion.

NZ shares rise, led by Arvida

Arvida Group led the New Zealand share market higher as investors were cheered by positive earnings reports and - like much of Asia - shrugged off news Moody's Investors Service cut its sovereign credit rating on China.

Cellmid achieves record quarterly sales for hair loss products

Cellmid (ASX:CDY) has achieved record sales of $1.51 million for the March quarter, up 120% from the same period last year.

Pacific Edge Release: Cxbladder Monitor Significantly Outperforms All Compared FDA Approved Urine Tests For Bladder Cancer; Enhancing The Standard Of Care For Bladder Cancer Patients

2017-04-12 devicespace
DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the prestigious international journal, Urologic Oncology. The peer reviewed scientific and clinical paper validates the superior performance of Pacific Edge's Cxbladder Monitor test for the surveillance of patients who are being managed for recurrence following treatment for bladder cancer, compared to existing alternatives.

NZ shares up, Sky TV and Westpac gain

New Zealand shares rose, led by Sky Network Television and Westpac Banking Corp, while Tegel Group Holdings and A2 Milk Co dropped.

Pacific Edge undertakes $8 million share placement

Cancer diagnostics company Pacific Edge has undertaken an $8 million share placement to institutional and other select investors in New Zealand in order to shore up its balance sheet.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...